Navigation Links
Actos Lawsuit News: Bernstein Liebhard LLP Notes Scheduling of Next Status Conference in Federal Actos Bladder Cancer Litigation
Date:9/14/2013

New York, NY (PRWEB) September 14, 2013

At least 2,500 Actos lawsuits (http://www.consumerinjurylawyers.com/actos/Actos-Lawsuit.html) that allege extended use of the Type 2 diabetes drug caused patients to develop bladder cancer continue to move forward in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. According to court documents, the Actos bladder cancer litigation will convene its next Status Conference on September 26, 2013. (In re: Actos Product Liability Litigation, MDL No. 2299)

“Our Firm continues to be contacted by Actos users who developed bladder cancer after using this medication for at least 12 months. We are pleased to see this proceeding moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos lawsuit evaluations to individuals who were diagnosed with bladder cancer following long-term use of the drug.

Actos Bladder Cancer Litigation
According to court documents, all of the Actos bladder cancer lawsuits pending in the Western District of Louisiana claim that Takeda Pharmaceuticals and other defendants concealed their knowledge of the bladder cancer risk associated with Actos, and failed to provide adequate warnings to the public and medical community. The federal litigation’s first bellwether trial will begin on January 27, 2014, while its second Actos bladder cancer trial will commence on April 14, 2014.

Additional Actos lawsuits involving bladder cancer allegations are also pending in various state courts. According to court documents, the nation’s second trial of an Actos bladder cancer claim is currently underway in Maryland State Court. The lawsuit, which was filed on behalf of an Actos user who died of bladder cancer last year, alleges that Takeda knew as early as 2005 that research had linked prolonged use of the drug to the disease cancer, but waited six years to issue a public warning. The complaint further alleges that the company’s conduct was motivated by a desire to increase Actos sales. (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland.)

The first trial involving Actos and bladder cancer concluded this past April in Los Angeles Superior court, with that jury awarding more than $6 million to a man who was diagnosed with bladder cancer after taking Actos for four years. However, court documents indicate that the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

The litigation involving Actos bladder cancer claims began to move forward in June 2011, after the U.S. Food & Drug Administration (FDA) warned that use of Actos for one year could increase a patient’s risk for the disorder. At that time, the FDA mandated that new information about the association between Actos and bladder cancer be added to the drug’s label.

Patients who took Actos for an extended period of time and later developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn More about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing
the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-bladder-cancer/prweb11123365.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. After Taking Diabetes Drug Actos for Nearly Seven Years, Florida Man Developed Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
2. Actos Lawsuit Filed By Wright & Schulte on Behalf of Ohio Man Alleges Extended Use of Type-2 Diabetes Drug Caused Him to Develop Bladder Cancer
3. Actos Bladder Cancer Lawsuits Move Forward, with Issuance of New Order in Federal Actos Litigation, Bernstein Liebhard LLP Reports
4. Lawsuit Alleges Takeda Pharmaceutical Co., Maker of Diabetes Drug Actos, Didn’t Warn of the Drug’s Risks Soon Enough; Parker Waichman LLP Responds
5. Actos Lawsuit News: Bernstein Liebhard LLP Notes Start of Second Actos Bladder Cancer Trial in Maryland State Court
6. Actos Bladder Cancer Lawsuits Help: Resource4thePeople Reports Number of Consolidated Federal Cases Climbs to over 2,500
7. Actos Lawsuits Move Forward Following Latest Status Conference in Federal Actos Bladder Cancer Litigation
8. Oregon Man Developed Bladder Cancer Brought on by Years of Ingesting Diabetes Drug Actos, Alleges Lawsuit Filed by Parker Waichman LLP
9. Florida Woman Developed Bladder Cancer After Taking Actos to Treat her Type II Diabetes, Alleges Lawsuit Filed by Parker Waichman LLP
10. Years of Ingesting Diabetes Drug Actos Caused Florida Man to Develop Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
11. Actos Lawsuits Alleging Bladder Cancer Update: Resource4thePeople Reports Judge Continues to Move Multidistrict Litigation Forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology: